Aqr Capital Management LLC Eagle Pharmaceuticals, Inc. Transaction History

Aqr Capital Management LLC

$64.6 Billion
Q2 2024

A detailed history of Aqr Capital Management LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 696,797 shares of EGRX stock, worth $278,718. This represents 0.01% of its overall portfolio holdings.

Number of Shares

696,797

Previous 879,073 20.74%

Holding current value

$278,718

Previous $4.61 Million 15.28%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.34 - $5.6 $608,801 - $1.02 Million	-182,276 Reduced 20.74%	696,797 $3.9 Million
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $1.64 Million - $2.51 Million	385,408 Added 78.07%	879,073 $4.61 Million
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $975,573 - $3.2 Million	210,707 Added 74.47%	493,665 $2.58 Million
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $1.29 Million - $1.95 Million	-85,015 Reduced 23.1%	282,958 $4.46 Million
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $1.82 Million - $3.27 Million	102,553 Added 38.64%	367,973 $7.15 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $3.26 Million - $4.44 Million	130,105 Added 96.15%	265,420 $7.53 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $984,212 - $1.57 Million	39,400 Added 41.08%	135,315 $3.96 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $1.18 Million - $2.1 Million	44,599 Added 86.91%	95,915 $2.53 Million
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $385,904 - $480,276	9,353 Added 22.29%	51,316 $2.28 Million
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $234,579 - $276,781	-5,262 Reduced 11.14%	41,963 $2.08 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $9,576 - $11,892	-209 Reduced 0.44%	47,225 $2.41 Million
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $362,274 - $461,467	-8,273 Reduced 14.85%	47,434 $2.65 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $210,175 - $253,739	-5,702 Reduced 9.29%	55,707 $2.38 Million
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $674,311 - $852,422	16,724 Added 37.43%	61,409 $2.56 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $868,360 - $1.07 Million	-20,814 Reduced 31.78%	44,685 $2.08 Million
Q3 2020 Nov 16, 2020	SELL	$37.02 - $51.28 $988,434 - $1.37 Million	-26,700 Reduced 28.96%	65,499 $2.78 Million
Q2 2020 Aug 17, 2020	SELL	$43.24 - $55.02 $2.27 Million - $2.88 Million	-52,418 Reduced 36.25%	92,199 $4.42 Million
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $588,448 - $1.03 Million	17,121 Added 13.43%	144,617 $6.65 Million
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $771,072 - $912,880	14,195 Added 12.53%	127,496 $7.66 Million
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $58,841 - $66,277	-1,105 Reduced 0.97%	113,301 $6.41 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $300,727 - $377,119	6,452 Added 5.98%	114,406 $6.37 Million
Q1 2019 May 14, 2019	BUY	$38.66 - $51.82 $406,664 - $545,094	10,519 Added 10.8%	107,954 $5.45 Million
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $1.07 Million - $1.97 Million	29,091 Added 42.57%	97,435 $3.93 Million
Q3 2018 Nov 15, 2018	BUY	$66.65 - $83.86 $1.37 Million - $1.72 Million	20,549 Added 42.99%	68,344 $4.74 Million
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $850,493 - $1.27 Million	-16,595 Reduced 25.77%	47,795 $3.62 Million
Q1 2018 May 15, 2018	SELL	$52.16 - $66.86 $4.93 Million - $6.32 Million	-94,479 Reduced 59.47%	64,390 $3.39 Million
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $2.07 Million - $2.54 Million	-41,765 Reduced 20.82%	158,869 $8.49 Million
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $9.35 Million - $12.1 Million	200,634	200,634 $12 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

9.89M

Call Options Held

1.01M

Put Options Held

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $5.21M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Eagle Pharmaceuticals, Inc. Transaction History